So, from the peak to correct around 15% kinds is I would say, but beyond that I would say then they start looking attractive again from a three to five years perspective because none of the problems are really balance sheet oriented problems, they are all more P&L related problems and more valuation issues.
Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge?
Aarti Pharmalabs shares have surged 33% in two days after the company reported a 65.4% year-on-year rise in Q1FY27 profit and 38.7% growth in revenue.